OptimizeRx Corp 8-K

What Happened
OptimizeRx Corporation announced that Chief Commercial Officer Theresa Greco agreed to separate from employment effective June 15, 2026 and will transition to a paid advisory role for 12 months. The Separation and Advisory Agreement was signed June 1, 2026, becomes effective June 9, 2026 if not revoked, and runs through June 15, 2027.

Key Details

• Separation date: June 15, 2026; advisory term through June 15, 2027.
• Cash payments and benefits: continuation of Ms. Greco’s $380,000 annual base salary for 12 months and a one‑time lump sum equal to her annual cash bonus target of $209,000.
• Benefits: reimbursement of COBRA premiums for health, dental and vision for up to 12 months.
• Other terms: previously granted equity will continue to vest during the advisory term; Ms. Greco is subject to a 12‑month non‑compete and 12‑month non‑solicit restrictions and will be bound by certain company policies. The Separation and Advisory Agreement also includes a general release of claims.

Why It Matters
This filing documents an executive transition and the company’s contractual commitments, including cash and benefit payments and continued equity vesting. Investors should note the short‑term cash and benefit obligations (salary continuation and bonus payment) and the retention of institutional knowledge through the 12‑month advisory arrangement, while restrictive covenants (non‑compete/non‑solicit) may limit Ms. Greco’s competitive activity after separation. The full Separation and Advisory Agreement will be filed as an exhibit to the Company’s Q2 2026 Form 10‑Q.